NOVELTY study animation
Watch our short animation to learn more about the NOVELTY study.Read More
If you are a member of the general public and not a healthcare professional, NOVELTY study investigator or AstraZeneca Medical employee, please CLICK HERE to see information tailored to you.
The NOVEL observational longiTudinal studY (NOVELTY) is a global, prospective, 3-year observational study of patients with a diagnosis or suspected diagnosis of asthma and/or COPD. NOVELTY aims to describe patient characteristics, treatment patterns and disease burden over time across the spectrum of obstructive lung disease, providing real-world evidence to advance the development of precision medicine to deliver the right treatment to the right patient at the right time. The NOVELTY study is sponsored by AstraZeneca.
Six NOVELTY ePosters were presented at the virtual ERS Congress 2020, and the related abstracts have now been published online.Read More
We are pleased to announce that ‘Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design’ has been published.Read More
Read summaries of publications and presentations relating to the NOVELTY study and access useful NOVELTY resources.Read More
Access news updates, research requests, resources and frequently asked questions relating to the NOVELTY study.Read More